ArticleJournal of gastrointestinal oncology2026
A nine-gene nicotine-metabolism signature predicts prognosis and characterizes the immune landscape in colon adenocarcinoma.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated single-cell and spatial transcriptomic analyses identify TRIP6 as a prognostic and EMT-associated biomarker in colorectal cancer.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Smoking is a preventable cause of colorectal cancer (CRC), and nicotine metabolism may promote tumorigenesis. We aimed to investigate the prognostic significance of nicotine metabolism‑related genes (NRGs) in colon adenocarcinoma (COAD) and to develop a gene signature for patient stratification. Methods: Using the Cancer Genome Atlas COAD cohort, we performed differential expression analysis and weighted gene co-expression network analysis to identify NRGs. Functional enrichment, Cox regression, and least absolute shrinkage and selection operator (LASSO) modelling were applied to build a multigene signature, which was validated in external cohorts. Single-cell transcriptomic data and immune infiltration analyses were used to evaluate gene expression patterns and tumor microenvironmental features. Results: We identified 767 differentially expressed NRGs enriched in extracellular matrix (ECM) organization and signaling pathways. A nine‑gene signature ( Conclusions: We propose a novel NRG-based prognostic signature that accurately predicts outcomes in COAD. The model highlights the interplay between nicotine metabolism, ECM remodeling, and immune responses, highlighting genes and pathways that may inform future therapeutic stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.